Replies to post #55136 on Ayala Pharmaceuticals Inc (fka ADXS)

[jckrdu]

Maybe the below bolded statement is referring to the Aim2serv trial. It wasn't clear to me from the PR, but that would make sense.

---------------------------
Below is the 2016 PR announcing the partnership with Stendhal.
http://ir.advaxis.com/press-release/business-development/advaxis-axalimogene-filolisbac-be-developed-and-commercialized

Under the terms of the Agreement, Stendhal will pay $10 million toward the expenses of AIM2CERV, a planned global Phase 3 clinical trial in women with high-risk, locally advanced cervical cancer. This payment covers a significant portion of the total planned study costs. Stendhal will also work with Advaxis to complete the clinical trial of axalimogene filolisbac in Mexico, Brazil, Colombia, and other investigational sites in Latin American countries. Additionally, Stendhal will manage the regulatory approval process, promotion, commercialization and market access for axalimogene filolisbac in these markets. Advaxis and Stendhal will share profits on a pre-determined basis.

[ignatiusrielly35]

I’ve always thought that this was exactly the plan. That Stendhal would use the Phase 3 data to piggyback Latin American approvals on the FDA application. I’m not sure I understand your question about separate trials.